{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:28:48Z","timestamp":1792614528801,"version":"4.5.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,6,17]],"date-time":"2019-06-17T00:00:00Z","timestamp":1560729600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,6,17]],"date-time":"2019-06-17T00:00:00Z","timestamp":1560729600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Parasites Vectors"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13071-019-3563-z","type":"journal-article","created":{"date-parts":[[2019,6,17]],"date-time":"2019-06-17T13:07:11Z","timestamp":1560776831000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["A novel praziquantel solid lipid nanoparticle formulation shows enhanced bioavailability and antischistosomal efficacy against murine S. mansoni infection"],"prefix":"10.1186","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5567-6708","authenticated-orcid":false,"given":"Amr","family":"Radwan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naglaa M.","family":"El-Lakkany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samia","family":"William","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina S.","family":"El-Feky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Y.","family":"Al-Shorbagy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samira","family":"Saleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanaa","family":"Botros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,17]]},"reference":[{"key":"3563_CR1","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41572-018-0013-8","volume":"4","author":"DP McManus","year":"2018","unstructured":"McManus DP, Dunne DW, Sacko M, Utzinger J, Vennervald BJ, Zhou X-N. Schistosomiasis. Nat Rev Dis Primers. 2018;4:13.","journal-title":"Nat Rev Dis Primers."},{"key":"3563_CR2","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/S0140-6736(16)31012-1","volume":"388","author":"H Wang","year":"2016","unstructured":"Wang H, Naghavi M, Allen C, Barber RM, Bhutta ZA, Carter A, et al. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980\u20132015: a systematic analysis for the global burden of disease study 2015. Lancet. 2016;388:1459\u2013544.","journal-title":"Lancet."},{"key":"3563_CR3","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.molbiopara.2014.06.002","volume":"195","author":"D Cioli","year":"2014","unstructured":"Cioli D, Pica-Mattoccia L, Basso A, Guidi A. Schistosomiasis control: praziquantel forever? Mol Biochem Parasitol. 2014;195:23\u20139.","journal-title":"Mol Biochem Parasitol."},{"key":"3563_CR4","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1017\/S0031182000007137","volume":"122","author":"S William","year":"2001","unstructured":"William S, Botros S, Ismail M, Farghally A, Day TA, Bennett JL. Praziquantel-induced tegumental damage in vitro is diminished in schistosomes derived from praziquantel-resistant infections. Parasitology. 2001;122:63\u20136.","journal-title":"Parasitology."},{"key":"3563_CR5","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.ijpara.2004.05.001","volume":"34","author":"D Cioli","year":"2004","unstructured":"Cioli D, Botros SS, Wheatcroft-Francklow K, Mbaye A, Southgate V, Tchuente LA, et al. Determination of ED50 values for praziquantel in praziquantel-resistant and -susceptible Schistosoma mansoni isolates. Int J Parasitol. 2004;34:979\u201387.","journal-title":"Int J Parasitol."},{"key":"3563_CR6","doi-asserted-by":"publisher","first-page":"e485","DOI":"10.1371\/journal.pntd.0000485","volume":"3","author":"PJ Hotez","year":"2009","unstructured":"Hotez PJ, Fenwick A. Schistosomiasis in Africa: an emerging tragedy in our new global health decade. PLoS Negl Trop Dis. 2009;3:e485.","journal-title":"PLoS Negl Trop Dis."},{"key":"3563_CR7","doi-asserted-by":"publisher","first-page":"e718","DOI":"10.1371\/journal.pntd.0000718","volume":"4","author":"PJ Hotez","year":"2010","unstructured":"Hotez PJ, Pecoul B. \u201cManifesto\u201d for advancing the control and elimination of neglected tropical diseases. PLoS Negl Trop Dis. 2010;4:e718.","journal-title":"PLoS Negl Trop Dis."},{"key":"3563_CR8","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.coph.2018.06.004","volume":"42","author":"G Panic","year":"2018","unstructured":"Panic G, Keiser J. Acting beyond 2020: better characterization of praziquantel and promising antischistosomal leads. Curr Opin Pharmacol. 2018;42:27\u201333.","journal-title":"Curr Opin Pharmacol."},{"key":"3563_CR9","doi-asserted-by":"publisher","first-page":"e3286","DOI":"10.1371\/journal.pntd.0003286","volume":"8","author":"J Zwang","year":"2014","unstructured":"Zwang J, Olliaro PL. Clinical efficacy and tolerability of praziquantel for intestinal and urinary schistosomiasis-a meta-analysis of comparative and non-comparative clinical trials. PLoS Negl Trop Dis. 2014;8:e3286.","journal-title":"PLoS Negl Trop Dis."},{"key":"3563_CR10","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/0169-4758(96)10029-6","volume":"12","author":"PG Fallon","year":"1996","unstructured":"Fallon PG, Tao LF, Ismail MM, Bennett JL. Schistosome resistance to praziquantel: fact or artifact? Parasitol Today. 1996;12:316\u201320.","journal-title":"Parasitol Today."},{"key":"3563_CR11","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/S1368-7646(98)80004-6","volume":"1","author":"PG Fallon","year":"1998","unstructured":"Fallon PG. Schistosome resistance to praziquantel. Drug Resist Update. 1998;1:236\u201341.","journal-title":"Drug Resist Update"},{"key":"3563_CR12","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1590\/S0074-02761987000800025","volume":"82","author":"JI Bruce","year":"1987","unstructured":"Bruce JI, Dias LC, Liang YS, Coles GC. Drug resistance in schistosomiasis: a review. Mem Inst Oswaldo Cruz. 1987;82:143\u201350.","journal-title":"Mem Inst Oswaldo Cruz."},{"key":"3563_CR13","doi-asserted-by":"publisher","first-page":"e1260","DOI":"10.1371\/journal.pntd.0001260","volume":"5","author":"M Woelfle","year":"2011","unstructured":"Woelfle M, Seerden JP, de Gooijer J, Pouwer K, Olliaro P, Todd MH. Resolution of praziquantel. PLoS Negl Trop Dis. 2011;5:e1260.","journal-title":"PLoS Negl Trop Dis."},{"key":"3563_CR14","doi-asserted-by":"publisher","first-page":"e2975","DOI":"10.1371\/journal.pntd.0002975","volume":"8","author":"J Keiser","year":"2014","unstructured":"Keiser J, Silue KD, Adiossan LK, N\u2019Guessan NA, Monsan N, Utzinger J, et al. Praziquantel, mefloquine-praziquantel, and mefloquine-artesunate-praziquantel against Schistosoma haematobium: a randomized, exploratory, open-label trial. PLoS Negl Trop Dis. 2014;8:e2975.","journal-title":"PLoS Negl Trop Dis."},{"key":"3563_CR15","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1046\/j.1365-3156.2000.00646.x","volume":"5","author":"J Utzinger","year":"2000","unstructured":"Utzinger J, N\u02bcGoran EK, N\u02bcDri A, Lengeler C, Tanner M. Efficacy of praziquantel against Schistosoma mansoni with particular consideration for intensity of infection. Trop Med Int Health. 2000;5:771\u20138.","journal-title":"Trop Med Int Health."},{"key":"3563_CR16","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/S0035-9203(03)00003-8","volume":"98","author":"G Raso","year":"2004","unstructured":"Raso G, N\u2019Goran EK, Toty A, Luginb\u00fchl A, Adjoua CA, Tian-Bi NT, et al. Efficacy and side effects of praziquantel against Schistosoma mansoni in a community of western C\u00f4te d\u2019Ivoire. Trans R Soc Trop Med Hyg. 2004;98:18\u201327.","journal-title":"Trans R Soc Trop Med Hyg."},{"key":"3563_CR17","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s13318-012-0089-6","volume":"37","author":"N El-Lakkany","year":"2012","unstructured":"El-Lakkany N, El-Din SHS, Heikal L. Bioavailability and in vivo efficacy of a praziquantel-polyvinylpyrrolidone solid dispersion in Schistosoma mansoni-infected mice. Eur J Drug Metab Pharmacokinet. 2012;37:289\u201399.","journal-title":"Eur J Drug Metab Pharmacokinet."},{"key":"3563_CR18","doi-asserted-by":"publisher","first-page":"3501","DOI":"10.1128\/AAC.04875-14","volume":"59","author":"GS El-Feky","year":"2015","unstructured":"El-Feky GS, Mohamed WS, Nasr HE, El-Lakkany NM, Seifel-Din SH, Botros SS. Praziquantel in a clay nanoformulation shows more bioavailability and higher efficacy against murine Schistosoma mansoni infection. Antimicrob Agents Chemother. 2015;59:3501\u20138.","journal-title":"Antimicrob Agents Chemother."},{"key":"3563_CR19","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jpba.2015.09.023","volume":"117","author":"M Malhado","year":"2016","unstructured":"Malhado M, Pinto DP, Silva AC, Silveira GP, Pereira HM, Santos JG Jr, et al. Preclinical pharmacokinetic evaluation of praziquantel loaded in poly (methyl methacrylate) nanoparticle using a HPLC-MS\/MS. J Pharm Biomed Anal. 2016;117:405\u201312.","journal-title":"J Pharm Biomed Anal."},{"key":"3563_CR20","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.actatropica.2016.06.002","volume":"161","author":"LD Silva","year":"2016","unstructured":"Silva LD, Arr\u00faa EC, Pereira DA, Fraga CM, Costa TLD, Hemphill A, et al. Elucidating the influence of praziquantel nanosuspensions on the in vivo metabolism of Taenia crassiceps cysticerci. Acta Trop. 2016;161:100\u20135.","journal-title":"Acta Trop."},{"key":"3563_CR21","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.msec.2016.05.119","volume":"68","author":"M Geszke-Moritz","year":"2016","unstructured":"Geszke-Moritz M, Moritz M. Solid lipid nanoparticles as attractive drug vehicles: composition, properties and therapeutic strategies. Mater Sci Eng C. 2016;68:982\u201394.","journal-title":"Mater Sci Eng C."},{"key":"3563_CR22","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.actatropica.2017.06.025","volume":"174","author":"F Tomiotto-Pellissier","year":"2017","unstructured":"Tomiotto-Pellissier F, Miranda-Sapla MM, Machado LF, Bortoleti BTDS, Sahd CS, Chagas AF, et al. Nanotechnology as a potential therapeutic alternative for schistosomiasis. Acta Trop. 2017;174:64\u201371.","journal-title":"Acta Trop."},{"key":"3563_CR23","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.ejpb.2016.08.001","volume":"108","author":"S Doktorovov\u00e1","year":"2016","unstructured":"Doktorovov\u00e1 S, Kova\u010devi\u0107 AB, Garcia ML, Souto EB. Preclinical safety of solid lipid nanoparticles and nanostructured lipid carriers: current evidence from in vitro and in vivo evaluation. Eur J Pharm Biopharm. 2016;108:235\u201352.","journal-title":"Eur J Pharm Biopharm."},{"key":"3563_CR24","doi-asserted-by":"publisher","first-page":"211","DOI":"10.2174\/1573413711309020008","volume":"9","author":"R Bhandari","year":"2013","unstructured":"Bhandari R, Indu PK. A method to prepare solid lipid nanoparticles with improved entrapment efficiency of hydrophilic drugs. Curr Nanosci. 2013;9:211\u201320.","journal-title":"Curr Nanosci."},{"key":"3563_CR25","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.nano.2010.06.003","volume":"6","author":"S Kheradmandnia","year":"2010","unstructured":"Kheradmandnia S, Vasheghani-Farahani E, Nosrati M, Atyabi F. Preparation and characterization of ketoprofen-loaded solid lipid nanoparticles made from beeswax and carnauba wax. Nanomedicine. 2010;6:753\u20139.","journal-title":"Nanomedicine."},{"key":"3563_CR26","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.colsurfa.2017.04.010","volume":"532","author":"RRR Mar\u00edn","year":"2017","unstructured":"Mar\u00edn RRR, Babick F, Hillemann L. Zeta potential measurements for non-spherical colloidal particles\u2014practical issues of characterisation of interfacial properties of nanoparticles. Colloids Surf A Physicochem Eng Asp. 2017;532:516\u201321.","journal-title":"Colloids Surf A Physicochem Eng Asp."},{"key":"3563_CR27","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S0378-4347(00)84351-0","volume":"275","author":"SH Xiao","year":"1983","unstructured":"Xiao SH, Catto BA, Webster LT Jr. Quantitative determination of praziquantel in serum by high-performance liquid chromatography. J Chromatogr. 1983;275:127\u201332.","journal-title":"J Chromatogr."},{"key":"3563_CR28","doi-asserted-by":"crossref","DOI":"10.1201\/b14095","volume-title":"Pharmacokinetics","author":"M Gibaldi","year":"1982","unstructured":"Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel Dekker Inc; 1982.","edition":"2"},{"key":"3563_CR29","first-page":"34","volume":"1","author":"Y Liang","year":"1987","unstructured":"Liang Y, Bruce J, Boyd D. Laboratory cultivation of schistosome vector snails and maintenance of schistosome life cycles. Proc First Sino-Am Symp. 1987;1:34\u201348.","journal-title":"Proc First Sino-Am Symp."},{"key":"3563_CR30","doi-asserted-by":"publisher","first-page":"483","DOI":"10.4269\/ajtmh.1967.16.483","volume":"16","author":"RH Duvall","year":"1967","unstructured":"Duvall RH, DeWitt WB. An improved perfusion technique for recovering adult schistosomes from laboratory animals. Am J Trop Med Hyg. 1967;16:483\u20136.","journal-title":"Am J Trop Med Hyg."},{"key":"3563_CR31","doi-asserted-by":"publisher","first-page":"696","DOI":"10.4269\/ajtmh.1977.26.696","volume":"26","author":"IA Kamel","year":"1977","unstructured":"Kamel IA, Cheever AW, Elwi AM, Mosimann JE, Danner R. Schistosoma-mansoni and S-Haematobium infections in Egypt. I. Evaluation of techniques for recovery of worms and eggs at necropsy. Am J Trop Med Hyg. 1977;26:696\u2013701.","journal-title":"Am J Trop Med Hyg."},{"key":"3563_CR32","doi-asserted-by":"publisher","first-page":"201","DOI":"10.4269\/ajtmh.1962.11.201","volume":"11","author":"J Pellegrino","year":"1962","unstructured":"Pellegrino J, Cunha AS, Faria J, Oliveira CA. New approach to screening of drugs in experimental Schistosomiasis mansoni in mice. Am J Trop Med Hyg. 1962;11:201\u201315.","journal-title":"Am J Trop Med Hyg."},{"key":"3563_CR33","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1208\/s12249-009-9193-6","volume":"10","author":"U Ruktanonchai","year":"2009","unstructured":"Ruktanonchai U, Bejrapha P, Sakulkhu U, Opanasopit P, Bunyapraphatsara N, Junyaprasert V, et al. Physicochemical characteristics, cytotoxicity, and antioxidant activity of three lipid nanoparticulate formulations of alpha-lipoic acid. AAPS PharmSciTech. 2009;10:227\u201334.","journal-title":"AAPS PharmSciTech."},{"key":"3563_CR34","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.apsb.2015.07.003","volume":"5","author":"S Kalepu","year":"2015","unstructured":"Kalepu S, Nekkanti V. Insoluble drug delivery strategies: review of recent advances and business prospects. Acta Pharm Sin B. 2015;5:442\u201353.","journal-title":"Acta Pharm Sin B."},{"key":"3563_CR35","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s40249-018-0444-1","volume":"7","author":"HB Weng","year":"2018","unstructured":"Weng HB, Chen HX, Wang MW. Innovation in neglected tropical disease drug discovery and development. Infect Dis Poverty. 2018;7:67.","journal-title":"Infect Dis Poverty."},{"key":"3563_CR36","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1258\/jrsm.2011.110180","volume":"104","author":"ZS Morris","year":"2011","unstructured":"Morris ZS, Wooding S, Grant J. The answer is 17 years, what is the question: understanding time lags in translational research. J R Soc Med. 2011;104:510\u201320.","journal-title":"J R Soc Med."},{"key":"3563_CR37","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.pt.2018.01.006","volume":"34","author":"TA Day","year":"2018","unstructured":"Day TA, Kimber MJ. Praziquantel interaction with mammalian targets in the spotlight. Trends Parasitol. 2018;34:263\u20135.","journal-title":"Trends Parasitol."},{"key":"3563_CR38","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.molbiopara.2010.05.003","volume":"173","author":"RS Kasinathan","year":"2010","unstructured":"Kasinathan RS, Morgan WM, Greenberg RM. Schistosoma mansoni express higher levels of multidrug resistance-associated protein 1 (SmMRP1) in juvenile worms and in response to praziquantel. Mol Biochem Parasitol. 2010;173:25\u201331.","journal-title":"Mol Biochem Parasitol."},{"key":"3563_CR39","first-page":"846","volume":"36","author":"R Chaiworaporn","year":"2005","unstructured":"Chaiworaporn R, Maneerat Y, Rojekittikhun W, Ramasoota P, Janecharut T, Matsuda H, et al. Therapeutic effect of subcurative dose praziquantel on Schistosoma mansoni infected mice and resistance to challenge infection after treatment. Southeast Asian J Trop Med Public Health. 2005;36:846\u201352.","journal-title":"Southeast Asian J Trop Med Public Health."},{"key":"3563_CR40","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S0939-6411(00)00087-4","volume":"50","author":"RH Muller","year":"2000","unstructured":"Muller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery\u2014a review of the state of the art. Eur J Pharm Biopharm. 2000;50:161\u201377.","journal-title":"Eur J Pharm Biopharm."},{"key":"3563_CR41","first-page":"86","volume":"64","author":"L Yang","year":"2009","unstructured":"Yang L, Geng Y, Li H, Zhang Y, You J, Chang Y. Enhancement the oral bioavailability of praziquantel by incorporation into solid lipid nanoparticles. Pharmazie. 2009;64:86\u20139.","journal-title":"Pharmazie."},{"key":"3563_CR42","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ijpharm.2013.12.022","volume":"463","author":"AL de Souza","year":"2014","unstructured":"de Souza AL, Andreani T, de Oliveira RN, Kiill CP, dos Santos FK, Allegretti SM, et al. In vitro evaluation of permeation, toxicity and effect of praziquantel-loaded solid lipid nanoparticles against Schistosoma mansoni as a strategy to improve efficacy of the schistosomiasis treatment. Int J Pharm. 2014;463:31\u20137.","journal-title":"Int J Pharm."},{"key":"3563_CR43","first-page":"289","volume":"2","author":"M Uner","year":"2007","unstructured":"Uner M, Yener G. Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives. Int J Nanomed. 2007;2:289\u2013300.","journal-title":"Int J Nanomed."},{"key":"3563_CR44","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/B978-0-323-46142-9.00030-X","volume-title":"Nanostructures for novel therapy","author":"S Doktorovova","year":"2017","unstructured":"Doktorovova S, Shegokar R, Souto EB. Role of excipients in formulation development and biocompatibility of lipid nanoparticles (SLNs\/NLCs). In: Ficai D, Grumezescu AM, editors. Nanostructures for novel therapy. Amsterdam: Elsevier; 2017. p. 811\u201343."},{"key":"3563_CR45","volume-title":"Bentley\u2019s textbook of pharmaceutics","author":"AO Bentley","year":"1977","unstructured":"Bentley AO, Rawlins EA. Bentley\u2019s textbook of pharmaceutics. London, UK: Bailli\u00cbre Tindall; 1977."},{"key":"3563_CR46","doi-asserted-by":"publisher","first-page":"E57","DOI":"10.3390\/pharmaceutics10020057","volume":"10","author":"M Danaei","year":"2018","unstructured":"Danaei M, Dehghankhold M, Ataei S, Davarani FH, Javanmard R, Dokhani A, et al. Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems. Pharmaceutics. 2018;10:E57.","journal-title":"Pharmaceutics."},{"key":"3563_CR47","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1080\/00034983.1980.11687327","volume":"74","author":"P Andrews","year":"1980","unstructured":"Andrews P, Dycka J, Frank G. Effect of praziquantel on clinical-chemical parameters in healthy and schistosome-infected mice. Ann Trop Med Parasitol. 1980;74:167\u201377.","journal-title":"Ann Trop Med Parasitol."},{"key":"3563_CR48","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1645\/GE-865R.1","volume":"92","author":"SS Botros","year":"2006","unstructured":"Botros SS, El-Din SHS, El-Lakkany NM, Sabra ANA, Ebeid FA. Drug-metabolizing enzymes and praziquantel bioavailability in mice harboring Schistosoma mansoni isolates of different drug susceptibilities. J Parasitol. 2006;92:1344\u20139.","journal-title":"J Parasitol."},{"key":"3563_CR49","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/0035-9203(90)90333-A","volume":"84","author":"ME Mandour","year":"1990","unstructured":"Mandour ME, El Turabi H, Homeida MM, El Sadig T, Ali HM, Bennett JL, et al. Pharmacokinetics of praziquantel in healthy volunteers and patients with schistosomiasis. Trans R Soc Trop Med Hyg. 1990;84:389\u201393.","journal-title":"Trans R Soc Trop Med Hyg."},{"key":"3563_CR50","doi-asserted-by":"publisher","first-page":"809","DOI":"10.4269\/ajtmh.1994.51.809","volume":"51","author":"MA El Guiniady","year":"1994","unstructured":"El Guiniady MA, El Touny MA, Abdel-Bary MA, Abdel-Fatah SA, Metwally A. Clinical and pharmacokinetic study of praziquantel in Egyptian schistosomiasis patients with and without liver cell failure. Am J Trop Med Hyg. 1994;51:809\u201318.","journal-title":"Am J Trop Med Hyg."},{"key":"3563_CR51","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1177\/030006059302100601","volume":"21","author":"AF Badawi","year":"1993","unstructured":"Badawi AF, Mostafa MH. Possible mechanisms of alteration in the capacities of carcinogen metabolizing enzymes during schistosomiasis and their role in bladder cancer induction. J Int Med Res. 1993;21:281\u2013305.","journal-title":"J Int Med Res."},{"key":"3563_CR52","first-page":"254","volume":"21","author":"PC Brant","year":"1979","unstructured":"Brant PC, Prata A. Altered drug metabolism in hepatosplenic schistosomiasis. Rev Inst Med Trop Sao Paulo. 1979;21:254\u20139.","journal-title":"Rev Inst Med Trop Sao Paulo."},{"key":"3563_CR53","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/0169-4758(88)90047-6","volume":"4","author":"BL Tekwanl","year":"1988","unstructured":"Tekwanl BL, Shukla OP, Ghatak S. Altered drug metabolism in parasitic diseases. Parasitol Today. 1988;4:4\u201310.","journal-title":"Parasitol Today."},{"key":"3563_CR54","first-page":"2367","volume":"6","author":"S Xie","year":"2011","unstructured":"Xie S, Pan B, Shi B, Zhang Z, Zhang X, Wang M, et al. Solid lipid nanoparticle suspension enhanced the therapeutic efficacy of praziquantel against tapeworm. Int J Nanomed. 2011;6:2367\u201374.","journal-title":"Int J Nanomed."},{"key":"3563_CR55","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jconrel.2014.10.026","volume":"197","author":"K Maisel","year":"2015","unstructured":"Maisel K, Ensign L, Reddy M, Cone R, Hanes J. Effect of surface chemistry on nanoparticle interaction with gastrointestinal mucus and distribution in the gastrointestinal tract following oral and rectal administration in the mouse. J Control Release. 2015;197:48\u201357.","journal-title":"J Control Release."},{"key":"3563_CR56","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.scp.2017.07.002","volume":"6","author":"P Ganesan","year":"2017","unstructured":"Ganesan P, Narayanasamy D. Lipid nanoparticles: different preparation techniques, characterization, hurdles, and strategies for the production of solid lipid nanoparticles and nanostructured lipid carriers for oral drug delivery. Sustain Chem Pharm. 2017;6:37\u201356.","journal-title":"Sustain Chem Pharm."},{"key":"3563_CR57","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/BF00389899","volume":"52","author":"R Gonnert","year":"1977","unstructured":"Gonnert R, Andrews P. Praziquantel, a new broad-spectrum antischistosomal agent. Z Parasitenkd. 1977;52:129\u201350.","journal-title":"Z Parasitenkd."},{"key":"3563_CR58","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.actatropica.2013.06.011","volume":"128","author":"TF Frezza","year":"2013","unstructured":"Frezza TF, Gremiao MP, Zanotti-Magalhaes EM, Magalhaes LA, de Souza AL, Allegretti SM. Liposomal-praziquantel: efficacy against Schistosoma mansoni in a preclinical assay. Acta Trop. 2013;128:70\u20135.","journal-title":"Acta Trop."},{"key":"3563_CR59","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.actatropica.2015.07.022","volume":"150","author":"TF Frezza","year":"2015","unstructured":"Frezza TF, de Souza ALR, Prado CCR, de Oliveira CNF, Gremi\u00e3o MPD, Giorgio S, et al. Effectiveness of hyperbaric oxygen for experimental treatment of Schistosomiasis mansoni using praziquantel-free and encapsulated into liposomes: assay in adult worms and oviposition. Acta Trop. 2015;150:182\u20139.","journal-title":"Acta Trop."},{"key":"3563_CR60","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.jddst.2018.03.009","volume":"45","author":"CSF Marques","year":"2018","unstructured":"Marques CSF, Rezende P, Andrade LN, Mendes TMF, Allegretti SM, Bani C, et al. Solid dispersion of praziquantel enhanced solubility and improve the efficacy of the schistosomiasis treatment. J Drug Deliv Sci Technol. 2018;45:124\u201334.","journal-title":"J Drug Deliv Sci Technol."},{"key":"3563_CR61","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1007\/BF00931515","volume":"78","author":"VS Delgado","year":"1992","unstructured":"Delgado VS, Suarez DP, Cesari IM, Incani RN. Experimental chemotherapy of Schistosoma mansoni with praziquantel and oxamniquine: differential effect of single or combined formulations of drugs on various strains and on both sexes of the parasite. Parasitol Res. 1992;78:648\u201354.","journal-title":"Parasitol Res."},{"key":"3563_CR62","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.pt.2009.09.007","volume":"25","author":"CE James","year":"2009","unstructured":"James CE, Hudson AL, Davey MW. An update on P-glycoprotein and drug resistance in Schistosoma mansoni. Trends Parasitol. 2009;25:538\u20139.","journal-title":"Trends Parasitol."},{"key":"3563_CR63","doi-asserted-by":"publisher","first-page":"e0140147","DOI":"10.1371\/journal.pone.0140147","volume":"10","author":"A Pinto-Almeida","year":"2015","unstructured":"Pinto-Almeida A, Mendes T, Armada A, Belo S, Carrilho E, Viveiros M, et al. The role of efflux pumps in Schistosoma mansoni praziquantel resistant phenotype. PLoS ONE. 2015;10:e0140147.","journal-title":"PLoS ONE."},{"key":"3563_CR64","doi-asserted-by":"publisher","first-page":"363","DOI":"10.4269\/ajtmh.1965.14.363","volume":"14","author":"J Pellegrino","year":"1965","unstructured":"Pellegrino J, Faria J. The oogram method for the screening of drugs in Schistosomiasis mansoni. Am J Trop Med Hyg. 1965;14:363\u20139.","journal-title":"Am J Trop Med Hyg."},{"key":"3563_CR65","doi-asserted-by":"publisher","first-page":"62","DOI":"10.4269\/ajtmh.1971.20.62","volume":"20","author":"AW Cheever","year":"1971","unstructured":"Cheever AW, Anderson LA. Rate of destruction of Schistosoma mansoni eggs in the tissues of mice. Am J Trop Med Hyg. 1971;20:62\u20138.","journal-title":"Am J Trop Med Hyg."},{"key":"3563_CR66","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1080\/00034983.1989.11812373","volume":"83","author":"F Richards Jr","year":"1989","unstructured":"Richards F Jr, Sullivan J, Ruiz-Tiben E, Eberhard M, Bishop H. Effect of praziquantel on the eggs of Schistosoma mansoni, with a note on the implications for managing central nervous system schistosomiasis. Ann Trop Med Parasitol. 1989;83:465\u201372.","journal-title":"Ann Trop Med Parasitol."},{"key":"3563_CR67","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1166\/jnn.2015.9186","volume":"15","author":"F Kolenyak-Santos","year":"2015","unstructured":"Kolenyak-Santos F, Garnero C, De Oliveira RN, De Souza ALR, Chorilli M, Allegretti SM, et al. Nanostructured lipid carriers as a strategy to improve the in vitro schistosomiasis activity of praziquantel. J Nanosci Nanotechnol. 2015;15:761\u201372.","journal-title":"J Nanosci Nanotechnol."},{"key":"3563_CR68","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1080\/15287390490425777","volume":"67","author":"MC Wiles","year":"2004","unstructured":"Wiles MC, Huebner HJ, Afriyie-Gyawu E, Taylor RJ, Bratton GR, Phillips TD. Toxicological evaluation and metal bioavailability in pregnant rats following exposure to clay minerals in the diet. J Toxicol Environ Health A. 2004;67:863\u201374.","journal-title":"J Toxicol Environ Health A."},{"key":"3563_CR69","doi-asserted-by":"publisher","first-page":"72","DOI":"10.4015\/S1016237205000111","volume":"17","author":"Y-H Lee","year":"2005","unstructured":"Lee Y-H, Tzong-Fu K, Bor-Yann C, Yi-Kai F, Yu-Ren W, Wu-Ching L, et al. Toxicity assessment of montmorillonite as a drug carrier for pharmaceutical applications: yeast and rats model. Biomed Eng Appl Basis Commun. 2005;17:72\u20138.","journal-title":"Biomed Eng Appl Basis Commun."},{"key":"3563_CR70","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.jddst.2017.03.023","volume":"39","author":"S Jayrajsinh","year":"2017","unstructured":"Jayrajsinh S, Shankar G, Agrawal YK, Bakre L. Montmorillonite nanoclay as a multifaceted drug-delivery carrier: a review. J Drug Deliv Sci Technol. 2017;39:200\u20139.","journal-title":"J Drug Deliv Sci Technol."}],"container-title":["Parasites &amp; Vectors"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13071-019-3563-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13071-019-3563-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13071-019-3563-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T09:13:03Z","timestamp":1609924383000},"score":1,"resource":{"primary":{"URL":"https:\/\/parasitesandvectors.biomedcentral.com\/articles\/10.1186\/s13071-019-3563-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,17]]},"references-count":70,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["3563"],"URL":"https:\/\/doi.org\/10.1186\/s13071-019-3563-z","relation":{},"ISSN":["1756-3305"],"issn-type":[{"value":"1756-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,17]]},"assertion":[{"value":"29 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethics approval was granted by the Institutional Review Board of Theodor Bilharz Research Institute as well as the Research Ethics Committee for Experimental and Clinical Studies at Faculty of Pharmacy, Cairo University (Permit Number: PO.3.4.3, 2014).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"304"}}